{"id":947,"date":"2026-10-05T03:52:17","date_gmt":"2026-10-05T03:52:17","guid":{"rendered":"https:\/\/poznayu.com\/en\/?p=947"},"modified":"2026-10-05T03:52:17","modified_gmt":"2026-10-05T03:52:17","slug":"empagliflozin-for-type-2-diabetes-treatment","status":"publish","type":"post","link":"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/","title":{"rendered":"Empagliflozin for Type 2 Diabetes Treatment"},"content":{"rendered":"<div style='text-align:right' class='yasr-auto-insert-visitor'><\/div><p class=\"isSelectedEnd\"><strong><span>Empagliflozin<\/span><\/strong><span> is a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used in modern medical practice to treat <\/span><strong><span>type 2 diabetes<\/span><\/strong><span>, chronic heart failure, and chronic kidney disease.<\/span><\/p>\n<p><!--more--><\/p>\n<p class=\"isSelectedEnd\"><span>The drug changed the way diabetes is treated by shifting the focus from glucose control alone to broader cardiovascular and kidney protection.<\/span><\/p>\n<h2><span>Discovery History and Brand Names<\/span><\/h2>\n<p><img decoding=\"async\" src=\"https:\/\/poznayu.com\/wp-content\/uploads\/2026\/10\/Empagliflozin-1.jpg\" class=\"aligncenter\" \/><\/p>\n<p>&nbsp;<\/p>\n<p class=\"isSelectedEnd\"><span>The history of the gliflozin drug class goes back to 1835, when French chemists first isolated the naturally occurring compound phlorizin from apple tree bark.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>For many years, phlorizin was used mainly as a research tool because the glucosuria it caused was accompanied by blocked glucose absorption in the intestine, while the compound itself was completely broken down by gastrointestinal enzymes when taken orally. It was not until the second half of the 20th century that scientists established that phlorizin inhibits the SGLT1 and SGLT2 transport proteins responsible for glucose reabsorption in the renal tubules. That discovery prompted the pharmaceutical industry to search for stable synthetic analogs.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>Boehringer Ingelheim, working with Eli Lilly, developed empagliflozin by replacing the O-glycosidic bond with a more stable C-glycoside structure, providing high selectivity for SGLT2 and greater resistance to metabolism.<\/span><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/poznayu.com\/wp-content\/uploads\/2026\/10\/Empagliflozin-2.jpg\" class=\"aligncenter\" \/><\/p>\n<p>&nbsp;<\/p>\n<p class=\"isSelectedEnd\"><span>In 2014, the drug received regulatory approval under the brand name Jardiance. The large EMPA-REG OUTCOME trial, completed in 2015, was the first major diabetes study to show that empagliflozin could reduce cardiovascular mortality and the risk of worsening kidney failure, helping make it one of the most widely used original drugs in the world.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>In international and Russian pharmaceutical markets, empagliflozin is available both as the single-drug product Jardiance and as part of fixed-dose combination medications.<\/span><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/poznayu.com\/wp-content\/uploads\/2026\/10\/Empagliflozin-3.jpg\" class=\"aligncenter\" \/><\/p>\n<p>&nbsp;<\/p>\n<p class=\"isSelectedEnd\"><span>The most common combination is empagliflozin with <\/span><strong><span>metformin<\/span><\/strong><span>, sold under the brand name Synjardy, along with two-drug and three-drug regimens that include DPP-4 inhibitors such as Glyxambi (empagliflozin + linagliptin).<\/span><\/p>\n<h2><span>How to Take Empagliflozin and Dosing Regimens<\/span><\/h2>\n<p class=\"isSelectedEnd\"><em><span>Empagliflozin<\/span><\/em><span> is taken by mouth once or twice a day, such as in the morning and at lunchtime, regardless of meals, with a small amount of water.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>The standard starting dose is 10 mg per day. Any adjustment should be made by a physician based on glycated hemoglobin (HbA1c), estimated glomerular filtration rate (eGFR), and individual tolerability.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>The treatment approach depends directly on the patient&#8217;s baseline glucose-control measurements:<\/span><\/p>\n<ul data-spread=\"false\">\n<li><span>For an HbA1c level of 6.5% to 7.5%: empagliflozin is often used as monotherapy when metformin is not tolerated or as the first medication added to dietary therapy. The starting dose is 10 mg per day, allowing glucose levels to normalize gradually without a significant risk of hypoglycemia.<\/span><\/li>\n<li><span>For an HbA1c level of 7.5% to 10.0%: empagliflozin 10 mg is recommended in combination with metformin. If target glucose levels are not reached after 8\u201312 weeks and kidney function remains adequate (eGFR above 45 mL\/min\/1.73 m\u00b2), the daily empagliflozin dose may be increased to 25 mg.<\/span><\/li>\n<li><span>For an HbA1c level above 10.0%: marked glucotoxicity requires prompt intensification of treatment, including empagliflozin with insulin or a three-drug regimen involving metformin, a DPP-4 inhibitor, or a GLP-1 receptor agonist. In this setting, empagliflozin at 10\u201325 mg may help reduce the need for exogenous insulin and maintain glycemic control after the acute phase has resolved.<\/span><\/li>\n<\/ul>\n<p class=\"isSelectedEnd\"><span>Empagliflozin should not be confused with metformin: these are <\/span><strong><span>different drugs with different mechanisms of action<\/span><\/strong><span>. Metformin primarily reduces glucose production by the liver and improves insulin sensitivity, while empagliflozin <\/span><strong><span>removes excess glucose through the kidneys<\/span><\/strong><span>.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>That distinction matters in significant insulin resistance. Metformin may have a limited effect on its own, whereas empagliflozin lowers blood glucose independently of insulin action by increasing urinary glucose excretion.<\/span><\/p>\n<h2><span>Mechanism of Action<\/span><\/h2>\n<p><img decoding=\"async\" src=\"https:\/\/poznayu.com\/wp-content\/uploads\/2026\/10\/Empagliflozin-4.jpg\" class=\"aligncenter\" \/><\/p>\n<p class=\"isSelectedEnd\"><span>Empagliflozin works by reversibly and highly selectively inhibiting sodium-glucose cotransporter 2 (SGLT2), which is located in the proximal convoluted tubules of the kidneys:<\/span><\/p>\n<ul data-spread=\"false\">\n<li><span>Under normal conditions, the kidneys filter about 180 grams of glucose per day, and SGLT2 reabsorbs up to 90% of that amount back into the bloodstream.<\/span><\/li>\n<li><span>Blocking this transporter lowers the kidney&#8217;s glucose threshold, causing excess glucose to be excreted in the urine at a rate of about 60 to 80 grams per day.<\/span><\/li>\n<\/ul>\n<p class=\"isSelectedEnd\"><span>Urinary glucose excretion works independently of insulin secretion by pancreatic beta cells and does not depend on how sensitive peripheral tissues are to insulin.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>Because the body loses glucose, it also loses roughly 240\u2013320 calories per day, which can contribute to a gradual reduction in body weight through a decrease in visceral fat. At the same time, sodium excretion produces mild osmotic diuresis, lowering both systolic and diastolic blood pressure without changing heart rate.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>The organ-protective effects of empagliflozin extend beyond blood glucose reduction. Sodium delivery to the macula densa in the renal tubules activates tubuloglomerular feedback, constricting the afferent arteriole and reducing intraglomerular hydrostatic pressure, which slows the development of nephrosclerosis.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>In the myocardium, the drug improves energy metabolism by shifting cells toward ketone-body utilization and reduces both preload and afterload on the left ventricle.<\/span><\/p>\n<h2><span>Benefits and Drawbacks of Treatment<\/span><\/h2>\n<p class=\"isSelectedEnd\"><span>Empagliflozin has a distinctive pharmacologic profile that combines glucose-lowering effects with organ protection. At the same time, pushing large amounts of glucose through the urinary tract creates specific risks that require medical supervision.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>The key clinical benefits of empagliflozin include:<\/span><\/p>\n<ol data-spread=\"false\" start=\"1\">\n<li><span>Minimal risk of hypoglycemia: urinary glucose excretion naturally declines as plasma glucose falls toward threshold levels, making monotherapy relatively safe.<\/span><\/li>\n<li><span>Weight and blood pressure reduction: osmotic diuresis and calorie loss can contribute to a sustained 2 to 4 kg weight reduction and a moderate blood-pressure-lowering effect.<\/span><\/li>\n<li><span>Cardiovascular and kidney protection: clinical evidence has shown a lower risk of hospitalization for heart failure, slower declines in glomerular filtration rate, and lower overall mortality in high-risk patients.<\/span><\/li>\n<li><span>Convenient dosing: taking one fixed-dose tablet daily does not require constant self-monitoring or complicated dose titration.<\/span><\/li>\n<\/ol>\n<p class=\"isSelectedEnd\"><span>The main drawbacks and potential adverse effects include:<\/span><\/p>\n<ol data-spread=\"false\" start=\"1\">\n<li><span>Genitourinary infections: higher glucose concentrations in the urine create conditions favorable to fungal growth, increasing the risk of candidal vulvovaginitis and balanitis.<\/span><\/li>\n<li><span>Risk of euglycemic diabetic ketoacidosis: a rare but serious condition in which ketone levels rise even when blood glucose remains normal or only mildly elevated.<\/span><\/li>\n<li><span>Dehydration and orthostatic hypotension: the mild diuretic effect can reduce circulating blood volume, especially in older adults or when loop diuretics are used at the same time.<\/span><\/li>\n<li><span>Reduced glucose-lowering effectiveness with impaired kidney function: when eGFR falls below 30 mL\/min\/1.73 m\u00b2, the glucose-lowering effect drops substantially, although the kidney-protective effect remains.<\/span><\/li>\n<\/ol>\n<h2><span>Combining Empagliflozin With Metformin<\/span><\/h2>\n<p><img decoding=\"async\" src=\"https:\/\/poznayu.com\/wp-content\/uploads\/2026\/10\/Empagliflozin-5.jpg\" class=\"aligncenter\" \/><\/p>\n<p>&nbsp;<\/p>\n<p class=\"isSelectedEnd\"><span>Combining empagliflozin with metformin is considered one of the most rational medication strategies for treating type 2 diabetes.<\/span><\/p>\n<p class=\"isSelectedEnd\"><strong><span>Metformin<\/span><\/strong><span> suppresses glucose production by the liver and improves insulin sensitivity in muscle tissue, while empagliflozin increases the excretion of excess glucose through the kidneys. Using these two distinct mechanisms together can produce a sustained reduction in HbA1c without placing additional strain on the pancreas or promoting weight gain.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>Fixed-dose combination tablets such as Synjardy were developed to make treatment easier to follow. Available strengths, including 5 mg or 12.5 mg of empagliflozin combined with 850 mg or 1000 mg of metformin, allow for a flexible twice-daily dosing schedule.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>Using a ready-made combination simplifies the daily regimen, reduces the number of tablets a patient has to take, and can improve long-term treatment adherence.<\/span><\/p>\n<h2><span>Empagliflozin and Bodybuilding<\/span><\/h2>\n<p class=\"isSelectedEnd\"><span>A reasonable question for athletes is: <\/span><strong><span>Am I going to lose all my muscle mass and water?<\/span><\/strong><\/p>\n<p class=\"isSelectedEnd\"><span>Empagliflozin may be undesirable for athletes because of <\/span><strong><span>osmotic diuresis<\/span><\/strong><span>: glucose is lost along with water and sodium, so inadequate fluid intake can make the muscles look less full and temporarily lower body weight because of fluid loss.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>This can be especially noticeable during a cutting phase, intense training, or periods of inadequate water intake.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>Using empagliflozin alongside performance-enhancing drugs requires extra caution. Dehydration, aggressive calorie or carbohydrate restriction, and intense exercise are factors that can increase the risk of <\/span><strong><span>euglycemic ketoacidosis<\/span><\/strong><span> with SGLT2 inhibitors. Empagliflozin is therefore not a tool for improving athletic performance or for &#8220;controlling blood sugar&#8221; in a healthy athlete.<\/span><\/p>\n<p class=\"isSelectedEnd\"><span>But if an athlete is taking it anyway, here is my advice:<\/span><\/p>\n<ul data-spread=\"false\">\n<li><strong><span>For natural athletes:<\/span><\/strong><span> avoid dehydration and aggressive carbohydrate restriction, especially before training; pay attention to how you feel and monitor blood glucose.<\/span><\/li>\n<li><strong><span>For athletes using performance-enhancing drugs:<\/span><\/strong><span> pay particularly close attention to hydration and electrolytes, and do not combine the drug with an aggressive cutting phase without medical supervision.<\/span><\/li>\n<li>For an athlete using performance-enhancing drugs during a bulking phase, empagliflozin may reduce water retention while also increasing diuresis and lowering intramuscular hydration, which can make the muscles look less full. It should not be taken specifically to control blood sugar during a bulk without a medical indication because the risks of dehydration and ketoacidosis remain.<\/li>\n<\/ul>\n<p><span>If an athlete using performance-enhancing drugs has a blood glucose level of around <\/span><strong><span>7 mmol\/L<\/span><\/strong><span>, for example, and a doctor has prescribed empagliflozin, the medication should be taken according to the prescribed regimen. During a bulking phase, particular attention should be paid to hydration, electrolytes, and adequate carbohydrate intake.<\/span><\/p>\n<div style='text-align:right' class='yasr-auto-insert-visitor'><\/div>","protected":false},"excerpt":{"rendered":"<p>Empagliflozin is a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used in modern medical practice to treat type 2 diabetes, [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":949,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"yasr_overall_rating":0,"yasr_post_is_review":"","yasr_auto_insert_disabled":"","yasr_review_type":"","footnotes":""},"categories":[148],"tags":[663,662,272,152],"class_list":["post-947","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-empagliflozin","tag-glucose-level","tag-health","tag-sugar"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Empagliflozin for Type 2 Diabetes Treatment<\/title>\n<meta name=\"description\" content=\"Learn how empagliflozin works, how it is dosed, its benefits and risks, combinations with metformin, and use in bodybuilding.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Empagliflozin for Type 2 Diabetes Treatment\" \/>\n<meta property=\"og:description\" content=\"Learn how empagliflozin works, how it is dosed, its benefits and risks, combinations with metformin, and use in bodybuilding.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Discover Something New Every Day!\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-05T03:52:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/poznayu.com\/en\/wp-content\/uploads\/2026\/10\/Empagliflozin-review.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"572\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Health Science\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Health Science\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Empagliflozin for Type 2 Diabetes Treatment","description":"Learn how empagliflozin works, how it is dosed, its benefits and risks, combinations with metformin, and use in bodybuilding.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Empagliflozin for Type 2 Diabetes Treatment","og_description":"Learn how empagliflozin works, how it is dosed, its benefits and risks, combinations with metformin, and use in bodybuilding.","og_url":"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/","og_site_name":"Discover Something New Every Day!","article_published_time":"2026-10-05T03:52:17+00:00","og_image":[{"width":1024,"height":572,"url":"https:\/\/poznayu.com\/en\/wp-content\/uploads\/2026\/10\/Empagliflozin-review.jpg","type":"image\/jpeg"}],"author":"Health Science","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Health Science","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/#article","isPartOf":{"@id":"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/"},"author":{"name":"Health Science","@id":"https:\/\/poznayu.com\/en\/#\/schema\/person\/607d2b43a9cd41016b941f7791ed69b2"},"headline":"Empagliflozin for Type 2 Diabetes Treatment","datePublished":"2026-10-05T03:52:17+00:00","mainEntityOfPage":{"@id":"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/"},"wordCount":1458,"commentCount":0,"image":{"@id":"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/poznayu.com\/en\/wp-content\/uploads\/2026\/10\/Empagliflozin-review.jpg","keywords":["Empagliflozin","glucose level","health","sugar"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/","url":"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/","name":"Empagliflozin for Type 2 Diabetes Treatment","isPartOf":{"@id":"https:\/\/poznayu.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/#primaryimage"},"image":{"@id":"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/poznayu.com\/en\/wp-content\/uploads\/2026\/10\/Empagliflozin-review.jpg","datePublished":"2026-10-05T03:52:17+00:00","author":{"@id":"https:\/\/poznayu.com\/en\/#\/schema\/person\/607d2b43a9cd41016b941f7791ed69b2"},"description":"Learn how empagliflozin works, how it is dosed, its benefits and risks, combinations with metformin, and use in bodybuilding.","breadcrumb":{"@id":"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/#primaryimage","url":"https:\/\/poznayu.com\/en\/wp-content\/uploads\/2026\/10\/Empagliflozin-review.jpg","contentUrl":"https:\/\/poznayu.com\/en\/wp-content\/uploads\/2026\/10\/Empagliflozin-review.jpg","width":1024,"height":572,"caption":"Empagliflozin for Type 2 Diabetes Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/poznayu.com\/en\/empagliflozin-for-type-2-diabetes-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/poznayu.com\/en\/"},{"@type":"ListItem","position":2,"name":"Empagliflozin for Type 2 Diabetes Treatment"}]},{"@type":"WebSite","@id":"https:\/\/poznayu.com\/en\/#website","url":"https:\/\/poznayu.com\/en\/","name":"Discover Something New Every Day!","description":"Your informational hub for useful tips, fascinating facts, in-depth reviews, top lists, and mysterious stories. Explore more!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/poznayu.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/poznayu.com\/en\/#\/schema\/person\/607d2b43a9cd41016b941f7791ed69b2","name":"Health Science","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/deb3d9e059a11e67dfb9ad4b37244824645c1cd700fa73f5dd1f7d6072809ebc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/deb3d9e059a11e67dfb9ad4b37244824645c1cd700fa73f5dd1f7d6072809ebc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/deb3d9e059a11e67dfb9ad4b37244824645c1cd700fa73f5dd1f7d6072809ebc?s=96&d=mm&r=g","caption":"Health Science"},"description":"I\u2019m Dr. Michael Carter, a 43-year-old American physician and medical researcher. I earned my MD from the University of Michigan Medical School and later completed an MPH at the Johns Hopkins Bloomberg School of Public Health, with a focus on public health and clinical research. I began my medical career at University of Michigan Health, where I worked in clinical practice and contributed to research on chronic disease prevention and the effectiveness of medical interventions. I later continued in academic medicine, focusing on internal medicine, metabolic health, preventive care, and the analysis of clinical data. My research interests include chronic disease, cardiovascular risk factors, metabolic disorders, disease prevention, and the evaluation of medical evidence. I\u2019m particularly interested in the quality of clinical research, the evidence behind treatment approaches, and how medical findings are interpreted and applied in real-world practice.","sameAs":["https:\/\/poznayu.com\/en\/category\/health\/"],"url":"https:\/\/poznayu.com\/en\/author\/health-science\/"},false]}},"yasr_visitor_votes":{"stars_attributes":{"read_only":false,"span_bottom":false},"number_of_votes":1,"sum_votes":5},"_links":{"self":[{"href":"https:\/\/poznayu.com\/en\/wp-json\/wp\/v2\/posts\/947","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/poznayu.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/poznayu.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/poznayu.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/poznayu.com\/en\/wp-json\/wp\/v2\/comments?post=947"}],"version-history":[{"count":1,"href":"https:\/\/poznayu.com\/en\/wp-json\/wp\/v2\/posts\/947\/revisions"}],"predecessor-version":[{"id":950,"href":"https:\/\/poznayu.com\/en\/wp-json\/wp\/v2\/posts\/947\/revisions\/950"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/poznayu.com\/en\/wp-json\/wp\/v2\/media\/949"}],"wp:attachment":[{"href":"https:\/\/poznayu.com\/en\/wp-json\/wp\/v2\/media?parent=947"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/poznayu.com\/en\/wp-json\/wp\/v2\/categories?post=947"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/poznayu.com\/en\/wp-json\/wp\/v2\/tags?post=947"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}